Transfer of gene-corrected autologous hematopoietic stem cells in patients with primary immunodeficiencies has emerged as a new therapeutic approach. Patients with various conditions lacking a suitable donor have been treated with retroviral vectors and a gene-addition strategy. Initial promising results were shadowed by the occurrence of malignancies in some of these patients. Current trials, developed in the last decade, use safer viral vectors to overcome the risk of genotoxicity and have led to improved clinical outcomes. This review reflects the progresses made in specific disorders, including adenosine deaminase deficiency, X-linked severe combined immunodeficiency, chronic granulomatous disease, and Wiskott-Aldrich syndrome.
from α1 via xlomafota.13 on Inoreader http://ift.tt/2ssWHnm
via IFTTT
Ιατρική Αλέξανδρος Γ. Σφακιανάκης,Αναπαύσεως 5 Άγιος Νικόλαος 72100 Κρήτη 00302841026182 Medical Articles by Alexandros G.Sfakianakis PhD,Anapafseos 5 Agios Nikolaos 72100 Crete Greece 00306932607174
! # Ola via Alexandros G.Sfakianakis on Inoreader
Παρασκευή 30 Ιουνίου 2017
Gene Therapy Approaches to Immunodeficiency
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου